Coordinatore | STICHTING VU-VUMC
Organization address
address: DE BOELELAAN 1105 contact info |
Nazionalità Coordinatore | Netherlands [NL] |
Sito del progetto | http://www.neurocypres.eu/ |
Totale costo | 14˙640˙209 € |
EC contributo | 11˙025˙000 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2007-A |
Funding Scheme | CP-IP |
Anno di inizio | 2008 |
Periodo (anno-mese-giorno) | 2008-02-01 - 2012-07-31 |
# | ||||
---|---|---|---|---|
1 |
STICHTING VU-VUMC
Organization address
address: DE BOELELAAN 1105 contact info |
NL (AMSTERDAM) | coordinator | 0.00 |
2 |
BEACTICA AB
Organization address
address: Box 567 contact info |
SE (UPPSALA) | participant | 0.00 |
3 |
CONSIGLIO NAZIONALE DELLE RICERCHE
Organization address
address: Piazzale Aldo Moro 7 contact info |
IT (ROMA) | participant | 0.00 |
4 |
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
DE (HEIDELBERG) | participant | 0.00 |
5 |
FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN NURNBERG
Organization address
address: SCHLOSSPLATZ 4 contact info |
DE (ERLANGEN) | participant | 0.00 |
6 |
HELLENIC PASTEUR INSTITUTE
Organization address
address: Vassilissis Sofias Avenue 127 contact info |
EL (ATHENS) | participant | 0.00 |
7 |
HIQSCREEN SARL
Organization address
address: RUE DE L'ATHENEE 15 contact info |
CH (GENEVE) | participant | 0.00 |
8 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 0.00 |
9 |
INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
FR (PARIS CEDEX 15) | participant | 0.00 |
10 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 0.00 |
11 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 0.00 |
12 |
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Organization address
address: CHRISTOU LADA 6 contact info |
EL (ATHENS) | participant | 0.00 |
13 |
PROTEOSYS AG
Organization address
address: CARL ZEISSSTRASSE 51 contact info |
DE (MAINZ) | participant | 0.00 |
14 |
REGULON AE
Organization address
address: "Grigoriou Afxentiou 7, Alimos" contact info |
EL (ATHENS) | participant | 0.00 |
15 |
SHEMYAKIN AND OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY - RUSSIAN ACADEMY OF SCIENCE
Organization address
address: UL. MIKLUKHO MAKLAYA 16/10 contact info |
RU (MOSCOW) | participant | 0.00 |
16 |
STICHTING HET NEDERLANDS KANKER INSTITUUT
Organization address
address: PLESMANLAAN 121 contact info |
NL (AMSTERDAM) | participant | 0.00 |
17 |
SYNAPTOLOGICS BV
Organization address
address: BURMANSTRAAT 7 contact info |
NL (AMSTERDAM) | participant | 0.00 |
18 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 0.00 |
19 |
UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
Organization address
address: VIA UNIVERSITA 4 contact info |
IT (MODENA) | participant | 0.00 |
20 |
UNIVERSITAT KONSTANZ
Organization address
address: UNIVERSITATSSTRASSE 10 contact info |
DE (KONSTANZ) | participant | 0.00 |
21 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | participant | 0.00 |
22 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 0.00 |
23 |
UNIVERSITY OF PATRAS
Organization address
address: UNIVERSITY CAMPUS RIO PATRAS contact info |
EL (RIO PATRAS) | participant | 0.00 |
24 |
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
Organization address
address: De Boelelaan 1105 contact info |
NL (AMSTERDAM) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Cys-loop receptors (CLRs) form a superfamily of structurally related neurotransmitter-gated ion channels, comprising nicotinic acetylcholine, glycine, GABA-A/C and serotonin (5HT3) receptors, crucial to function of the peripheral and central nervous system. CLRs cover a wide spectrum of functions, ranging from muscle contraction to cognitive functions. CLR (mal)function is linked to various disorders, including muscular dystrophies, neurodegenerative diseases, e.g. Alzheimer’s and Parkinson’s, and neuropsychiatric diseases, e.g. schizophrenia, epilepsy and addiction. CLRs are potentially important drug targets for treatment of disease. However, novel drug discovery strategies call for in depth understanding of ligand binding sites, the structure-function relationships of these receptors and insight into their actions in the nervous system. NeuroCypres assembles the expertise of leading European laboratories to provide a technology workflow, which enables to embark on this next step in CLR structure and function. A major target of this project is to obtain high-resolution X-ray and NMR structures for CLRs and their complexes with diverse ligands, agonists/antagonists, channel blockers and modulators, which will reveal basic mechanisms of receptor functioning from ligand binding to gating and open new avenues to rational drug design. In addition, the project aims at understanding receptor function in the context of the brain, focusing on receptor biosensors, receptor-protein interactions and transgenic models. This major challenge requires application and development of a multidisciplinary workflow of high-throughput (HT) crystallization and HT-electrophysiology technologies, X-ray analysis, NMR and computational modeling, fragment-based drug design, innovative quantitative methods of interaction-proteomics, sensitive methods for visualization of activity and localization of receptors and studies of in vitro and in vivo function in animal models of disease.'
European scientists worked to provide novel insight into the structure and function of the neurotransmitter receptors known as Cys-loop receptors (CLRs). The generated knowledge could be implemented towards the design of new effective treatments for various diseases such as myasthenia gravis, epilepsy and schizophrenia.